CTX-130
CRISPR Therapeutics AG
[]
$crsp crispr therapeutics presents positive results from its phase 1 cobalt -lym trial of ctx130 in relapsed or refractory t cell malignancies at the 2022 european hematology association (eha) congress
The information in these Market Commentaries do not constitute a solicitation of the purchase or sale of any stocks ,  or options contracts.